VEGFA and neoplasm: Anti-angiogenic therapies selectively inhibit tumor vascular endothelial growth factor (VEGF) signaling pathways and suppress tumor neovascularization and microenvironment remodeling, this mechanistic approach had been shown clinical efficacy across multiple solid tumors (16).